Continued Early Intervention for Recent-onset Schizophrenia

Schizophrenia Clinical Trial

Official title:

Continued Early Intervention for Recent-onset Schizophrenia. A Randomized Controlled Study.

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00184509
• Other study ID #: SHDIR-1992-1995; NFR-1997-1999
• Status: Terminated
• Phase: Phase 3
• First received: September 15, 2005
• Last updated: January 25, 2017
• Start date: February 1993
• Est. completion date: May 1998

Study information

• Verified date: January 2017
• Source: Norwegian University of Science and Technology
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study was to determine whether outreach integrated treatment of first episode schizophrenia was more effecive than standard outpatient treatment.

Description:

Early intervention for schizophrenia has spawned considerable enthusiasm among clinicians without solid research evidence to suport its benefits and costs. The present study is a random-controlled study of integrated biomedical and psychosocial treatment on a population of recent-onset cases.

Comparison(s): 50 consecutive referrals with schizophrenic disorders of less than two years duration were allocated randomly to a comprehensive model of integrated treatment or standard care for two years. Main outcome measures was psychopathology, psychosocial functioning and hospital admissions.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 50
• Est. completion date: May 1998
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 35 Years

Eligibility

Inclusion Criteria:

• first-episode schizophrenia

Exclusion Criteria:

• acute psychosis

Related Conditions & MeSH terms

• Schizophrenia

Intervention

Behavioral:
• integrated psychosocial treatment (behavior)

Locations

Country	Name	City	State
Norway	Norwegian University of Science and Technology	Trondheim

Sponsors (2)

Lead Sponsor	Collaborator
Norwegian University of Science and Technology	The Research Council of Norway

Country where clinical trial is conducted

Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rehospitalizations and psychotic relapse at two years
Secondary	Psychopathology, psychosocial changes, functioning, antipsychotic medication